Biotesserae Camunity is a nanobody-based platform for the production of a new class of therapeutics for canine cancer.
The company was formed by Chris Cebra, chair of the Department of Clinical Sciences, and colleagues Shay Bracha, Dan Mourich, and Carl Ruby.
No comments!